<?xml version="1.0" encoding="UTF-8"?>
<ref id="B31-vaccines-07-00074">
 <label>31.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Mikell</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Sather</surname>
    <given-names>D.N.</given-names>
   </name>
   <name>
    <surname>Kalams</surname>
    <given-names>S.A.</given-names>
   </name>
   <name>
    <surname>Altfeld</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Alter</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Stamatatos</surname>
    <given-names>L.</given-names>
   </name>
  </person-group>
  <article-title>Characteristics of the earliest cross-neutralizing antibody response to HIV-1</article-title>
  <source>PLoS Pathog.</source>
  <year>2011</year>
  <volume>7</volume>
  <elocation-id>e1001251</elocation-id>
  <pub-id pub-id-type="doi">10.1371/annotation/8b3b24b5-d4ed-483a-b233-0a88513ad499</pub-id>
  <pub-id pub-id-type="pmid">21249232</pub-id>
 </element-citation>
</ref>
